Entries |
Document | Title | Date |
20090042993 | IDENTIFICATION OF NOVEL POST-TRANSLATIONAL PROTEIN MODIFICATIONS - Compositions and methods for post-translational modifications that include protein acetylation in the ER lumen and deacetylation in the Golgi apparatus are provided. The disclosed methods are especially suited for the identification of compounds useful for the prevention or treatment of neurodegenerative diseases such as Alzheimer's. | 02-12-2009 |
20090054526 | INHIBITORS OF ANOREXIC LIPID HYDROLYSIS FOR THE TREATMENT OF EATING DISORDERS - Compounds, pharmaceuticals, cosmetic or dietary supplements for the treatment of overweight, obesity and/or type II diabetes in a mammal (e.g. human) comprising a compound with formula I or formula II for example ceramidase-inhibitor, such as (1S,2R)-D-ery-thro-2-(N-myristoylamino)-1-phenyl-1-propanol, alone or in combination with an anorexic lipid (or other appetite-inhibiting acylamides or oleoyl-estrone), and methods of treatment comprising administration of said compounds, pharmaceuticals, cosmetic or a dietary supplements. The compounds, pharmaceuticals, cosmetic or dietary supplements and methods of the invention may further be used in modifying the feeding behaviour, suppression of hunger, enhancement of satiety, reduction of energy intake, reduction of fat tissue mass/lean mass ratio in a mammal (e.g. human). | 02-26-2009 |
20090082464 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE - Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed. | 03-26-2009 |
20090124699 | Silicone Material for Releasing an Active Molecule - The invention concerns a material, preferably adhesive, for releasing an active molecule for cosmetic use or personal care or a pharmaceutically or biologically active molecule for pharmaceutical use, which is formed of a silicone substance, preferably adhesive, wherein is incorporated said molecule and a compatibility agent wherein said active molecule is soluble, said compatibility agent being selected among isopropyl myristate, isopropyl palmitate, isononyl isononanoate, neopentyl glycol dioctanoate, branched paraffins, organofunctional silicones, or a silicone oil consisting of a cyclic concatenation of 4, 5, 6 or 7 D-siloxyl units of formula: (R) | 05-14-2009 |
20090197966 | Use of Hypothermia Inducing Drugs - The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a vanilloid receptor agonists, capsaicinoid or capsaicinoid-like agonist capable of inducing hypothermia, thereby benefiting patients suffering from illnesses characterized by tissue anoxia. | 08-06-2009 |
20090239951 | Crystalline Material - The invention relates to novel crystalline forms of 3-[[3,5-dibromo-4-[4-hydroxy-3-(1-methylethyl)-phenoxy]-phenyl]-amino]-3-oxopropanoic acid, said crystalline forms being characterised by a powder X-ray diffraction pattern having major peaks at either 2θ=16.1±0.2, 20.1±0.2, 20.7±0.2, and 24.2+0.2; or 2θ=9.0±0.2, 14.7±0.2, 19.6±0.2, 21.6±0.2, and 24.3+0.2. | 09-24-2009 |
20090247640 | ANTIMICROBIALS HAVING POLYQUATERNARY AMMONIUMS AND ALCOHOL-BEARING AMIDOAMINES AND METHODS FOR THEIR USE - Antimicrobial or preservative compositions with high user comfort and/or low ocular irritation. The compositions comprise a polyquaternary ammonium compound and an amidoamine having an alcohol group and exhibit synergistic antimicrobial activity. The compositions may be used as stand-alone antimicrobials/preservatives or may be incorporated into other ocular compositions such as those for ocular lens care or the treatment of ocular conditions. | 10-01-2009 |
20090306215 | DEUTERIUM-ENRICHED ARFORMOTEROL - The present application describes deuterium-enriched arformoterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 12-10-2009 |
20090312430 | COLCHICINE SOLID-STATE FORMS; METHODS OF MAKING; AND METHODS OF USE THEREOF - Disclosed are new colchicine solid-state forms, methods of preparing the solid-state forms, as well as formulations prepared therefrom and uses thereof. | 12-17-2009 |
20090318561 | COLCHICINE PRODUCTS, METHOD OF MANUFACTURE, AND METHODS OF USE - Disclosed herein is a method of using colchicine. In one embodiment, the method comprises administering to a patient colchicine and a substrate of cytochrome P450 1A2 and monitoring the patient during administration of colchicine and the substrate for an adverse event. Also disclosed are articles of manufacture comprising a container containing a dosage form of colchicine and a method of manufacturing a colchicine product. | 12-24-2009 |
20100029778 | HAIR AND/OR SCALP TREATMENT COMPOSITIONS - Hair and/or scalp treatment compositions comprise an antidandruff agent, an effective amount of a cannabinoid receptor (CBR) activating agent and a cosmetically acceptable diluent or carrier. Alternatively, the compositions may be shampoo compositions comprising from 3 to 50 wt % surfactant, a CB receptor activating agent and a cosmetically acceptable diluent or carrier, provided that the CB receptor activating agent is not palmitoylethanolamide. The compositions are useful in the treatment and/or prevention of the symptoms of dandruff and can reduce scalp itch, a symptom which is typically associated with dandruff. | 02-04-2010 |
20100041764 | THERAPEUTIC AGENT FOR DIABETIC NEUROPATHY - A therapeutic agent for the treatment of diabetic neuropathy which comprises (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]-ethyl]dimethylsulfonium p-toluenesulfonate of the formula (1) as an active ingredient. | 02-18-2010 |
20100099771 | USE OF COOLING AGENTS TO RELIEVE MILD OCULAR IRRITATION AND ENHANCE COMFORT - Ophthalmic compositions containing very low concentrations (e.g., 1 to 50 ppm) of cooling agents are described. The cooling agents are less volatile and less prone to causing ocular discomfort than agents previously utilized to obtain an ocular cooling effect, such as menthol. The cooling agents are preferably contained in a vehicle that forms a gel or partial gel upon application to the eye. | 04-22-2010 |
20100105780 | COLCHICINE COMPOSITIONS AND METHODS - Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed. | 04-29-2010 |
20100168244 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 07-01-2010 |
20100173995 | Use of PPAR-alpha activator as inflammatory skin disease-treating agent and method for treating skin diseases using the same - Disclosed herein is the use of a non-natural compound represented by the following formula 1 as an activator of the peroxisome proliferator activated receptor-α (PPAR-α) which shows an anti-inflammatory effect on inflammatory skin diseases. The PPAR-α activator increases the expression of PPAR-α in the skin to enhance various physiological effects of PPAR-α, that is, the anti-inflammatory effect caused by inhibiting the activity of transcription factors such as the nuclear factor κK (NF-κK) that induces inflammatory reactions, the effect of improving the epidermal permeability barrier function of the skin, and the effect of promoting the terminal differentiation of epidermal keratinocytes. Thus, the PPAR-α activator is useful for the treatment, alleviation or amelioration of skin diseases such as acne, seborrheic dermatitis, viral skin diseases, urticaria, pruritus, viral infectious diseases and contact dermatitis. | 07-08-2010 |
20100227929 | TRANSDERMAL COMPOSITIONS - The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C | 09-09-2010 |
20100261797 | NEW POLYMORPHIC FORMS OF N-[4-(TRIFLUOROMETHYL)BENZYL]-4-METHOXYBUTYRAMIDE - Crystalline polymorphic forms of a compound of formula N-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide are described. The two polymorphic forms, named polymorphic Form A and polymorphic Form B, can be used in the treatment of drug addiction and alcoholism and have very good stability. Methods for preparing the polymorphic forms are also described. | 10-14-2010 |
20100305209 | Articles of Manufacture Releasing an Active Ingredient - The present invention relates to articles of manufacture having a formulation distributed therein, wherein the formulation comprises an active agent which manifests a desirable property when released from the articles of manufacture. The present invention also relates to methods for manufacturing these articles of manufacture, to vehicles for applying the formulation to these articles of manufacture, and to perception indicators indicating the presence and the amount of formulation comprising an active agent applied to an article of manufacture. | 12-02-2010 |
20110046225 | Pharmaceutical formulation containing palmitoyl ethanolamide and stearoyl ethanolamide - The invention concerns new pharmaceutical formulations containing a blend of palmitoyl ethanolamide or PEA and stearoyl ethanolamide or SEA compounds as active principles. The formulation is suitable for oral, parenteral, topical, transdermic, rectal, sublingual, nasal, topical, transdermic, rectal, nasal or sublingual administration, whereby the dosage form of said formulations can be in patches, suppositories, ovules, pessaries, aerosol or spray, emulsions, suspensions, solutions. Said pharmaceutical formulations are useful for the treatment or prevention of skin pathologies, for the treatment or prevention of gynaecological pathologies, for the treatment of disorders or pathologies characterised by improper metabolism of fatty acids as well as for the treatment of disorders or pathologies characterised by inflammatory states | 02-24-2011 |
20110263714 | Reverse Vesicle - The reverse vesicle composition of the present invention includes (A) a sphingosine represented by formula (1) (wherein R | 10-27-2011 |
20110306672 | CERAMIDE-ANALOGOUS METABOLITES - This invention relates to certain ceramide-analogues of FTY720 (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; fingolimod). In particular, the present invention relates to pharmaceutical compositions comprising these compounds, as well as processes for their preparation and their use in the treatment of autoimmune conditions, such as multiple sclerosis. | 12-15-2011 |
20130005819 | CONTACT LENS DISINFECTING SOLUTIONS - This invention relates to ophthalmic disinfecting and preserving compositions. More particularly, this invention relates to multi-purpose disinfecting solutions [MPDS] suitable for use in or with storage cases for treating multiple-use contact lenses and/or for preserving, disinfecting or packaging of contact and other ophthalmic lenses. | 01-03-2013 |
20130035395 | WATER-BASED COSMETIC AND MANUFACTURING METHOD THEREOF - A water-based cosmetic that includes: (A) ceramidic compound-containing particles that include a ceramidic compound and that are dispersed as an oil phase in an aqueous phase; (B) a fatty acid component composed of at least one selected from the group consisting of fatty acids and fatty acid salts; and (C) a polyhydric alcohol component that includes a first polyhydric alcohol having an IOB of 2.2 or more and a total content in the composition of from 3% by mass to 20% by mass, and a second polyhydric alcohol having an IOB of 2.0 or less and a total content in the composition of 0% by mass or not more than 3% by mass, wherein a total content of surfactant in the composition is 0% by mass or not more than 1% by mass, and a total mass of ceramidic compound in the composition is at least 3.0 times a total mass of the fatty acid component in the composition. | 02-07-2013 |
20130102679 | Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease - The invention provides a use of panthenol or dexpanthenol in the prevention and/or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided. | 04-25-2013 |
20130178534 | N-Nonanoylvanillylamine as an agent for reducing the appetite, as an agent for imparting a feeling of fullness and as a mood enhancer, and corresponding substance mixtures, orally consumable products and methods - There is described primarily N-nonanoylvanillylamine for use in a therapeutic method as (a) an agent for reducing the appetite and/or (b) an agent for imparting a feeling of fullness and/or (c) a mood enhancer, as well as the non-therapeutic use of N-nonanoylvanillylamine as (a) an agent for reducing the appetite and/or (b) an agent for imparting a feeling of fullness and/or (c) a mood enhancer. The non-therapeutic use of corresponding substance mixtures is also further described. Finally, the invention relates also to orally consumable products (in particular foodstuffs, feeds and medicaments) comprising N-nonanoylvanillylamine, wherein the N-nonanoylvanillylamine is present in a concentration that (a) reduces the appetite and/or (b) brings about a feeling of fullness and/or (c) enhances the mood, but which concentration is low. | 07-11-2013 |
20130203855 | Pharmaceutical Dopamine Glycoconjugate Compositions and Methods of Their Preparation and Use - Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds and methods of their use. | 08-08-2013 |
20140018434 | CLEANING, INSECTICIDE, INSECT REPELLANT, GLUE SOLVENT AND ANTI-IRRITATION COMPOSITION - Exemplary embodiments of the present invention relate to pesticides, insecticides, insect repellant, insect anti-feeding, cleaning, glue dissolving and anti-irritation and wound healing compositions for humans and animals and, more particularly, to such compositions which are effective in killing, removing and/or repelling a wide range of endoparasites, ectoparasites and insects while also being non-toxic to humans, animals, and the environment. An exemplary embodiment of the present invention is directed to an aqueous composition including a mixture of at least one ethanolamide and at least one esterified fatty acid. Another exemplary embodiment of the present invention is directed to an aqueous composition including at least one esterified fatty acid in water and at least one emulsifier. The aqueous compositions may be used as a cleaning composition, insecticide, insect repellant, glue solvent or to relieve irritation from and/or promote healing of insect bites, skin abrasions superficial burns and wounds. | 01-16-2014 |
20140194522 | Emulsion Composition - Provided is an emulsion composition comprising the following ingredients (A), (B), (C), (D), (E), and (F):
| 07-10-2014 |
20150094373 | COMPOUNDS FOR TREATING INFLAMMATION AND PAIN - The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 04-02-2015 |
20150133560 | N-Methyl-N-Acylglucamine-Containing Composition - The invention relates to a surfactant concentrate which contains at least one anionic surfactant, an N-methyl-N-acylglucamine, a solvent and optionally one or more additives. The invention also relates to a method for producing the surfactant concentrate. The invention further relates to a method for producing cosmetic, dermatological or pharmaceutical compositions. | 05-14-2015 |
20160074345 | Composition for Prevention and Treatment of Contact Lens Papillary Conjunctivitis and Allergic Eye Disease - The invention provides a use of panthenol or dexpanthenol in the prevention and/or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided. | 03-17-2016 |
20160120990 | COMPOSITION FOR APPLICATION TO A MUCOSA COMPRISING A HYDROXYALKYL METHYLCELLULOSE - A composition designed for application to a mucosa comprises a tonicity-adjusting agent, a hydroxyalkyl methylcellulose and a liquid diluent, wherein the hydroxyalkyl methylcellulose has a DS of from 1.6 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, and at least 55 weight percent of the liquid diluent is water. When the composition comprises additionally a physiologically active agent, the composition may be used for transmucosal administration of the physiologically active agent to an individual. | 05-05-2016 |